FindTrial
Sign In

Evaluate the effects of propofol combined with dexmedetomidine or remifentanil in endoscopic ultrasound

Evaluate the effects of propofol combined with dexmedetomidine or remifentanil in endoscopic ultrasound

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034987
Enrollment
Unknown
Registered
2020-07-26
Start date
2020-08-20
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastrointestinal disease

Interventions

PD group:propofol and dexmedetomidine
PR group:propofol and remifentanil

Sponsors

Shandong Cancer Hospital and Institute
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients scheduled for painless endoscopic ultrasound will be enrolled from August 2020 to August 2021.

Exclusion criteria

Exclusion criteria: Patients aged 75 years, inability to understand Mandarin, post-op unsupervised, pregent and lactating women, BMI > 30kg/m2, patients with end-organ disease, asthma,COPD,sleep apnea, drug abuse, a known hypersensitivity to propofol or dexmedetomidine or remifentanil, an expected operation duration > 60 min, for any reason the anesthesia protocol or endoscopic procedure was changed.

Design outcomes

Primary

MeasureTime frame
level of satisfaction of endoscopist;—

Secondary

MeasureTime frame
induction time;dose of propofol;side effects;MOAA/S scale;discharge Aldrete score;awaking time;Incidence of hypotension;bradycardia;Incidence of desaturation;satisfaction of patients;—

Countries

China

Contacts

Public ContactWang Xiuqin

Shandong Cancer Hospital and Institute affiliated to Shandong First Medical University

jasmine75@163.com+86 13665416586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026